Evidence map›Paper›PMID 37361368›Full record

ArticleBreast cancer (Dove Medical Press)2023

Detecting the Frequency of c.5946delT Pathogenic Variant in the

Nega Berhane, Zemene Chekol, Aynias Seid

Open access · goldAbstract read
In one paragraph

Article in Breast cancer (Dove Medical Press), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Nega BerhaneDepartment of Medical Biotechnology, Institute of Biotechnology, University of Gondar, Gondar, Ethiopia.ORCID 0000-0003-1492-2746
Zemene ChekolDepartment of Medical Biotechnology, Institute of Biotechnology, University of Gondar, Gondar, Ethiopia.ORCID 0009-0005-9703-3689
Aynias SeidDepartment of Medical Biotechnology, Institute of Biotechnology, University of Gondar, Gondar, Ethiopia.ORCID 0000-0002-1304-7129
University of Gondar · ETDebre Tabor University · ET

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Breast cancer is one of the most common cancers and the leading cause of death for women worldwide, and the problem is currently getting worse. In Ethiopia, it has become one of the most prevalent cancers, with high rates of morbidity and mortality. The Objective: The aim of the present study was to detect the presence of the c.5946delT pathogenic variant in the Methods: A cross-sectional study was conducted from September 2021 to October 2022. Peripheral blood samples were collected from 100 patients with breast cancer, and gDNA was extracted using the salting-out method as per the protocol provided in the manufacturer's instructions. The Results: In this study, we discovered that 2% of breast cancer patients had a c.5946delT pathogenic variant of the Conclusion: We have found out that breast cancer patients in the study area had the

Indexed as

BRCA2 genebreast cancerpathogenic variantrisk factors

Identifiers

PMID37361368
PMCPMC10289093
OpenAlexW4381167195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.